Want to join the conversation?
During 2Q16, $GILD's HCV revenues in the US were $2.3Bil, up 13% sequentially and down 33% YoverY. The company said that in terms of patient starts, approx. 59,000 people began using re-therapy in the quarter. The company said that new patients are being identified through increased screening efforts using third-party data resources.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.